Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960703 | 0.94 | KCNH2 (0.41) | CYP2D6KCNH2CYP11B1CYP11B2HRH3 | |
| SCHEMBL24951670 | 0.90 | CYP2D6 (0.35) | CYP2D6KCNH2HRH3 | |
| SCHEMBL15960697 | 0.89 | CYP2D6 (0.39) | CYP2D6HRH3 | |
| SCHEMBL15960708 | 0.88 | RORC (0.33) | CYP2D6KCNH2CYP11B1CYP11B2 | |
| SCHEMBL25081710 | 0.85 | CYP2D6 (0.37) | CYP2D6 | |
| SCHEMBL15960715 | 0.82 | KCNH2 (0.36) | CYP2D6KCNH2 | |
| SCHEMBL15960712 | 0.81 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9963383 | 0.80 | RORC (0.31) | — | |
| SCHEMBL8064563 | 0.78 | CYP2D6 (0.41) | CYP2D6HRH3 | |
| SCHEMBL12267734 | 0.78 | CYP2D6 (0.35) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-9353123-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2015019365-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2015-02-12 | — | — | WO | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-09-05 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011050063-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | CYP2D6 1098/4885KCNH2 3015/4885CYP11B1 238/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CYP2D6 4405/4885KCNH2 4661/4885CYP11B1 2383/4885 |
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | SULT1E1, SULT2A1, SULT1A1 | CYP2D6 103/4885KCNH2 503/4885CYP11B1 183/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP2D6 1147/4885KCNH2 409/4885CYP11B1 219/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CYP2D6 3131/4885KCNH2 4497/4885CYP11B1 2069/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | CYP2D6 419/4885KCNH2 3314/4885CYP11B1 149/4885 |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | PCSK9, CFTR, SLC10A1 | CYP2D6 256/4885KCNH2 3197/4885CYP11B1 18/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CYP2D6 3131/4885KCNH2 4497/4885CYP11B1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.